Skip to main content
Top
Gepubliceerd in: Quality of Life Research 1/2016

05-07-2015

Health-related quality of life in patients with prominent negative symptoms: results from a multicenter randomized Phase II trial on bitopertin

Auteurs: Diana Rofail, Antoine Regnault, Stéphanie le Scouiller, Carmen Galani Berardo, Daniel Umbricht, Ray Fitzpatrick

Gepubliceerd in: Quality of Life Research | Uitgave 1/2016

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Abstract

Purpose

Symptoms of schizophrenia fall into three categories (positive, negative and cognitive symptoms), which probably impact differently on patient’s health-related quality of life (HRQoL). The present study aimed to explore HRQoL in patients with prominent negative symptoms.

Methods

In the 323 patients with prominent negative symptoms included in a multicenter Phase II trial investigating the safety and efficacy of bitopertin, HRQoL was assessed using the Schizophrenia Quality of Life Scale (SQLS), symptoms severity using the Positive and Negative Syndrome Scale and functioning using the Personal and Social Performance Scale. SQLS measurement properties were assessed; HRQoL was compared between treatment arms, and relationships between HRQoL, symptoms and functioning at baseline were explored.

Results

Both SQLS scores (Vitality/Cognition and Psychosocial Feelings) demonstrated good test–retest (ICC = 0.77 and 0.74) and internal consistency reliability (Cronbach’s α = 0.86 and 0.93). Clinical validity with regard to schizophrenia severity and ability to detect change in severity of symptoms of schizophrenia were satisfactory. The SQLS structure was not formally disconfirmed. No statistically significant difference was observed between treatment arms. Negative symptoms were more strongly associated with functioning than positive symptoms. Functioning and Anxiety/Depression were strongly related to both SQLS domains.

Conclusion

Overall, SQLS measurement properties were supported in these patients with prominent negative symptoms of schizophrenia. The impact of negative symptoms on functioning and HRQoL suggests that improving these symptoms will be a meaningful benefit in this population of patients.
Literatuur
2.
go back to reference McCabe, R., Saidi, M., & Priebe, S. (2007). Patient-reported outcomes in schizophrenia. British Journal of Psychiatry. Supplement, 50, s21–s28. CrossRef McCabe, R., Saidi, M., & Priebe, S. (2007). Patient-reported outcomes in schizophrenia. British Journal of Psychiatry. Supplement, 50, s21–s28. CrossRef
3.
5.
go back to reference Folsom, D. P., Depp, C., Palmer, B. W., Mausbach, B. T., Golshan, S., Fellows, I., et al. (2009). Physical and mental health-related quality of life among older people with schizophrenia. Schizophrenia Research, 108(1–3), 207–213. PubMedPubMedCentralCrossRef Folsom, D. P., Depp, C., Palmer, B. W., Mausbach, B. T., Golshan, S., Fellows, I., et al. (2009). Physical and mental health-related quality of life among older people with schizophrenia. Schizophrenia Research, 108(1–3), 207–213. PubMedPubMedCentralCrossRef
6.
go back to reference Wilkinson, G., Hesdon, B., Wild, D., Cookson, R., Farina, C., Sharma, V., et al. (2000). Self-report quality of life measure for people with schizophrenia: The SQLS. British Journal of Psychiatry, 177(42–6), 42–46. PubMedCrossRef Wilkinson, G., Hesdon, B., Wild, D., Cookson, R., Farina, C., Sharma, V., et al. (2000). Self-report quality of life measure for people with schizophrenia: The SQLS. British Journal of Psychiatry, 177(42–6), 42–46. PubMedCrossRef
7.
go back to reference Rouillon, F., Eriksson, L., Burba, B., Raboch, J., Kaprinis, G., & Schreiner, A. (2013). Functional recovery results from the risperidone long-acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Acta Neuropsychiatrica, 25(5), 297–306. PubMedCrossRef Rouillon, F., Eriksson, L., Burba, B., Raboch, J., Kaprinis, G., & Schreiner, A. (2013). Functional recovery results from the risperidone long-acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Acta Neuropsychiatrica, 25(5), 297–306. PubMedCrossRef
8.
go back to reference Mortimer, A. M., & Al-Agib, A. O. (2007). Quality of life in schizophrenia on conventional versus atypical antipsychotic medication: A comparative cross-sectional study. International Journal of Social Psychiatry, 53(2), 99–107. PubMedCrossRef Mortimer, A. M., & Al-Agib, A. O. (2007). Quality of life in schizophrenia on conventional versus atypical antipsychotic medication: A comparative cross-sectional study. International Journal of Social Psychiatry, 53(2), 99–107. PubMedCrossRef
9.
go back to reference Shirazi-Southall, S., Rodriguez, D. E., & Nomikos, G. G. (2002). Effects of typical and atypical antipsychotics and receptor selective compounds on acetylcholine efflux in the hippocampus of the rat. Neuropsychopharmacology, 26(5), 583–594. PubMedCrossRef Shirazi-Southall, S., Rodriguez, D. E., & Nomikos, G. G. (2002). Effects of typical and atypical antipsychotics and receptor selective compounds on acetylcholine efflux in the hippocampus of the rat. Neuropsychopharmacology, 26(5), 583–594. PubMedCrossRef
10.
go back to reference Hill, S. K., Bishop, J. R., Palumbo, D., & Sweeney, J. A. (2010). Effect of second-generation antipsychotics on cognition: Current issues and future challenges. Expert Review of Neurotherapeutics, 10(1), 43–57. PubMedPubMedCentralCrossRef Hill, S. K., Bishop, J. R., Palumbo, D., & Sweeney, J. A. (2010). Effect of second-generation antipsychotics on cognition: Current issues and future challenges. Expert Review of Neurotherapeutics, 10(1), 43–57. PubMedPubMedCentralCrossRef
11.
go back to reference Leucht, S., Corves, C., Arbter, D., Engel, R. R., Li, C., & Davis, J. M. (2009). Second-generation versus first-generation antipsychotic drugs for schizophrenia: A meta-analysis. Lancet, 373(9657), 31–41. PubMedCrossRef Leucht, S., Corves, C., Arbter, D., Engel, R. R., Li, C., & Davis, J. M. (2009). Second-generation versus first-generation antipsychotic drugs for schizophrenia: A meta-analysis. Lancet, 373(9657), 31–41. PubMedCrossRef
12.
go back to reference Tandon, R., Nasrallah, H. A., & Keshavan, M. S. (2010). Schizophrenia, “just the facts” 5. Treatment and prevention. Past, present, and future. Schizophrenia Research, 122(1–3), 1–23. PubMedCrossRef Tandon, R., Nasrallah, H. A., & Keshavan, M. S. (2010). Schizophrenia, “just the facts” 5. Treatment and prevention. Past, present, and future. Schizophrenia Research, 122(1–3), 1–23. PubMedCrossRef
13.
go back to reference Malhotra, A. K., Pinals, D. A., Weingartner, H., Sirocco, K., Missar, C. D., Pickar, D., et al. (1996). NMDA receptor function and human cognition: The effects of ketamine in healthy volunteers. Neuropsychopharmacology, 14(5), 301–307. PubMedCrossRef Malhotra, A. K., Pinals, D. A., Weingartner, H., Sirocco, K., Missar, C. D., Pickar, D., et al. (1996). NMDA receptor function and human cognition: The effects of ketamine in healthy volunteers. Neuropsychopharmacology, 14(5), 301–307. PubMedCrossRef
14.
go back to reference Noetzel, M. J., Jones, C. K., & Conn, P. J. (2012). Emerging approaches for treatment of schizophrenia: Modulation of glutamatergic signaling. Discovery of Medicine, 14(78), 335–343. Noetzel, M. J., Jones, C. K., & Conn, P. J. (2012). Emerging approaches for treatment of schizophrenia: Modulation of glutamatergic signaling. Discovery of Medicine, 14(78), 335–343.
15.
go back to reference Pinard, E., Alanine, A., Alberati, D., Bender, M., Borroni, E., Bourdeaux, P., et al. (2010). Selective GlyT1 inhibitors: discovery of [4-(3-fluoro-5-trifluoromethylpyridin-2-yl)piperazin-1-yl][5-methanesulfonyl-2-((S)-2,2,2-trifluoro-1-methylethoxy)phenyl]methanone (RG1678), a promising novel medicine to treat schizophrenia. Journal of Medicinal Chemistry, 53(12), 4603–4614. PubMedCrossRef Pinard, E., Alanine, A., Alberati, D., Bender, M., Borroni, E., Bourdeaux, P., et al. (2010). Selective GlyT1 inhibitors: discovery of [4-(3-fluoro-5-trifluoromethylpyridin-2-yl)piperazin-1-yl][5-methanesulfonyl-2-((S)-2,2,2-trifluoro-1-methylethoxy)phenyl]methanone (RG1678), a promising novel medicine to treat schizophrenia. Journal of Medicinal Chemistry, 53(12), 4603–4614. PubMedCrossRef
16.
go back to reference Umbricht, D., Alberati, D., Martin-Facklam, M., Borroni, E., Youssef, E. A., Ostland, M., et al. (2014). Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: A randomized, double-blind, proof-of-concept study. JAMA Psychiatry, 71(6), 637–646. PubMedCrossRef Umbricht, D., Alberati, D., Martin-Facklam, M., Borroni, E., Youssef, E. A., Ostland, M., et al. (2014). Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: A randomized, double-blind, proof-of-concept study. JAMA Psychiatry, 71(6), 637–646. PubMedCrossRef
17.
go back to reference Marder, S. R., Davis, J. M., & Chouinard, G. (1997). The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: Combined results of the North American trials. Journal of Clinical Psychiatry, 58(12), 538–546. PubMedCrossRef Marder, S. R., Davis, J. M., & Chouinard, G. (1997). The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: Combined results of the North American trials. Journal of Clinical Psychiatry, 58(12), 538–546. PubMedCrossRef
18.
go back to reference Martin, C. R., & Allan, R. (2007). Factor structure of the Schizophrenia Quality of Life Scale Revision 4 (SQLS-R4). Psychology, Health and Medicine, 12(2), 126–134. PubMedCrossRef Martin, C. R., & Allan, R. (2007). Factor structure of the Schizophrenia Quality of Life Scale Revision 4 (SQLS-R4). Psychology, Health and Medicine, 12(2), 126–134. PubMedCrossRef
19.
go back to reference Kay, S. R., Fiszbein, A., & Opler, L. A. (1987). The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin, 13(2), 261–276. PubMedCrossRef Kay, S. R., Fiszbein, A., & Opler, L. A. (1987). The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin, 13(2), 261–276. PubMedCrossRef
20.
go back to reference Patrick, D. L., Burns, T., Morosini, P., Rothman, M., Gagnon, D. D., Wild, D., et al. (2009). Reliability, validity and ability to detect change of the clinician-rated Personal and Social Performance scale in patients with acute symptoms of schizophrenia. Current Medical Research and Opinion, 25(2), 325–338. PubMedCrossRef Patrick, D. L., Burns, T., Morosini, P., Rothman, M., Gagnon, D. D., Wild, D., et al. (2009). Reliability, validity and ability to detect change of the clinician-rated Personal and Social Performance scale in patients with acute symptoms of schizophrenia. Current Medical Research and Opinion, 25(2), 325–338. PubMedCrossRef
21.
go back to reference Schumacker, R. E., & Lomax, R. G. (1996). A beginner’s guide to structural equation modeling. Mahwah, NJ: Lawrence Erlbaum Associates. Schumacker, R. E., & Lomax, R. G. (1996). A beginner’s guide to structural equation modeling. Mahwah, NJ: Lawrence Erlbaum Associates.
22.
go back to reference Chassany, O., Sagnier, P., Marquis, P., Fullerton, S., & Aaronson, N. (2002). Patient-reported outcomes: The example of health-related quality of life: A European guidance document for the improved integration of health-related quality of life assessment in the drug regulatory process. Drug Information Journal, 36, 209–238. CrossRef Chassany, O., Sagnier, P., Marquis, P., Fullerton, S., & Aaronson, N. (2002). Patient-reported outcomes: The example of health-related quality of life: A European guidance document for the improved integration of health-related quality of life assessment in the drug regulatory process. Drug Information Journal, 36, 209–238. CrossRef
23.
go back to reference Zumbo, B. D. (1999). A handbook on the Theory and Methods of Differential Item Functioning (DIF): Logistic Regression Modeling as a Unitary Framework for Binary and Likert-type (Ordinal) Item Scores. Ottawa, ON: Directorate of Human Resources Research and Evaluation, Department of National Defense. Zumbo, B. D. (1999). A handbook on the Theory and Methods of Differential Item Functioning (DIF): Logistic Regression Modeling as a Unitary Framework for Binary and Likert-type (Ordinal) Item Scores. Ottawa, ON: Directorate of Human Resources Research and Evaluation, Department of National Defense.
24.
go back to reference Gelin, M. N., & Zumbo, B. D. (2003). Differential Item Functioning results may change depending on how an item is scored: an illustration with the Center for Epidemiologic Studies Depression Scale. Educational and Psychological Measurement, 63(1), 65–74. CrossRef Gelin, M. N., & Zumbo, B. D. (2003). Differential Item Functioning results may change depending on how an item is scored: an illustration with the Center for Epidemiologic Studies Depression Scale. Educational and Psychological Measurement, 63(1), 65–74. CrossRef
25.
go back to reference Jodoin, M. G., & Gierl, M. J. (2001). Evaluating Type I error and power rates using an effect size measure with the logistic regression procedure for DIF detection. Applied Measurement in Education, 14, 329–349. CrossRef Jodoin, M. G., & Gierl, M. J. (2001). Evaluating Type I error and power rates using an effect size measure with the logistic regression procedure for DIF detection. Applied Measurement in Education, 14, 329–349. CrossRef
26.
go back to reference Hays, R. D., Anderson, R. & Revicki, D. (1998). Assessing reliability and validity of measurement in clinical trials. In Quality of life assessment in clinical trials: Methods and practice (pp. 169–182). Oxford: Oxford University Press. Hays, R. D., Anderson, R. & Revicki, D. (1998). Assessing reliability and validity of measurement in clinical trials. In Quality of life assessment in clinical trials: Methods and practice (pp. 169–182). Oxford: Oxford University Press.
27.
go back to reference Nunnally, J. C., & Bernstein, I. H. (1994). Psychometric theory. New York: McGraw-Hill Inc. Nunnally, J. C., & Bernstein, I. H. (1994). Psychometric theory. New York: McGraw-Hill Inc.
28.
go back to reference Guyatt, G. H., Deyo, R. A., Charlson, M., Levine, M. N., & Mitchell, A. (1989). Responsiveness and validity in health status measurements: A clarification. Journal of Clinical Epidemiology, 42(5), 403–408. PubMedCrossRef Guyatt, G. H., Deyo, R. A., Charlson, M., Levine, M. N., & Mitchell, A. (1989). Responsiveness and validity in health status measurements: A clarification. Journal of Clinical Epidemiology, 42(5), 403–408. PubMedCrossRef
29.
go back to reference Cohen, J. (1977). Statistical power analysis for the behavioral sciences. New York: Academic Press. Cohen, J. (1977). Statistical power analysis for the behavioral sciences. New York: Academic Press.
30.
go back to reference Kline, R. B. (2005). Principle and practice of structural equation modeling. New York: Guilford Press. Kline, R. B. (2005). Principle and practice of structural equation modeling. New York: Guilford Press.
31.
go back to reference Wilson, I. B., & Cleary, P. D. (1995). Linking clinical variables with health-related quality of life. A conceptual model of patient outcomes. JAMA, 273(1), 59–65. PubMedCrossRef Wilson, I. B., & Cleary, P. D. (1995). Linking clinical variables with health-related quality of life. A conceptual model of patient outcomes. JAMA, 273(1), 59–65. PubMedCrossRef
32.
go back to reference Arango, C., Nasrallah, H., Lawrie, S., Ochi Lohmann, T., Zhu, J., Garibaldi, G., et al. (2013) Efficacy and safety of adjunctive bitopertin (5 and 10 mg) versus placebo in subjects with persistent predominant negative symptoms of schizophrenia treated with antipsychotics—Results from the Phase III DayLyte study. In 4th Biennial Schizophrenia International Research Society Conference, 5–9 April 2013. Florence, Italy. Arango, C., Nasrallah, H., Lawrie, S., Ochi Lohmann, T., Zhu, J., Garibaldi, G., et al. (2013) Efficacy and safety of adjunctive bitopertin (5 and 10 mg) versus placebo in subjects with persistent predominant negative symptoms of schizophrenia treated with antipsychotics—Results from the Phase III DayLyte study. In 4th Biennial Schizophrenia International Research Society Conference, 5–9 April 2013. Florence, Italy.
33.
go back to reference Blaetter, T., Bugarski-Kirola, D., Fleischhacker, W. W., Bressan, R. A., Arango, C., Abi-Saab, D., et al. (2013). Efficacy and safety of adjunctive bitopertin (10 and 20 mg) versus placebo in subjects with persistent predominant negative symptoms of schizophrenia treated with antipsychotics—Results from the Phase III FlashLyte Study. In 4th Biennial Schizophrenia International Research Society Conference, 5–9 April 2013. Florence, Italy. Blaetter, T., Bugarski-Kirola, D., Fleischhacker, W. W., Bressan, R. A., Arango, C., Abi-Saab, D., et al. (2013). Efficacy and safety of adjunctive bitopertin (10 and 20 mg) versus placebo in subjects with persistent predominant negative symptoms of schizophrenia treated with antipsychotics—Results from the Phase III FlashLyte Study. In 4th Biennial Schizophrenia International Research Society Conference, 5–9 April 2013. Florence, Italy.
34.
go back to reference Taha, N. A., Ibrahim, M. I., Rahman, A. F., Shafie, A. A., & Rahman, A. H. (2012). Validation of the Schizophrenia Quality of Life Scale Revision 4 among Chronic Schizophrenia Patients in Malaysia. Value in Health Regional Issues, 1(1), 82–86. CrossRef Taha, N. A., Ibrahim, M. I., Rahman, A. F., Shafie, A. A., & Rahman, A. H. (2012). Validation of the Schizophrenia Quality of Life Scale Revision 4 among Chronic Schizophrenia Patients in Malaysia. Value in Health Regional Issues, 1(1), 82–86. CrossRef
35.
go back to reference Wilkinson, G., Clayson, D., Wild, D., Doll, H., Martin, C., & De Hert, M. (2004) The development and psychometric validation of the Schizophrenia Quality of Life Scale-revision 4 (SQLS-R4). Abstracts of the XIIth Biennal Winter Workshop on Schizophrenia. Schizophrenia Research. July 2, 2004. Wilkinson, G., Clayson, D., Wild, D., Doll, H., Martin, C., & De Hert, M. (2004) The development and psychometric validation of the Schizophrenia Quality of Life Scale-revision 4 (SQLS-R4). Abstracts of the XIIth Biennal Winter Workshop on Schizophrenia. Schizophrenia Research. July 2, 2004.
36.
go back to reference Galuppi, A., Turola, M. C., Nanni, M. G., Mazzoni, P., & Grassi, L. (2010). Schizophrenia and quality of life: How important are symptoms and functioning? International Journal of Mental Health Systems, 4, 31. PubMedPubMedCentralCrossRef Galuppi, A., Turola, M. C., Nanni, M. G., Mazzoni, P., & Grassi, L. (2010). Schizophrenia and quality of life: How important are symptoms and functioning? International Journal of Mental Health Systems, 4, 31. PubMedPubMedCentralCrossRef
37.
go back to reference Lipkovich, I. A., Deberdt, W., Csernansky, J. G., Sabbe, B., Keefe, R. S., & Kollack-Walker, S. (2009). Relationships among neurocognition, symptoms and functioning in patients with schizophrenia: A path-analytic approach for associations at baseline and following 24 weeks of antipsychotic drug therapy. BMC Psychiatry, 9, 44. PubMedPubMedCentralCrossRef Lipkovich, I. A., Deberdt, W., Csernansky, J. G., Sabbe, B., Keefe, R. S., & Kollack-Walker, S. (2009). Relationships among neurocognition, symptoms and functioning in patients with schizophrenia: A path-analytic approach for associations at baseline and following 24 weeks of antipsychotic drug therapy. BMC Psychiatry, 9, 44. PubMedPubMedCentralCrossRef
38.
go back to reference Rabinowitz, J., Levine, S. Z., Garibaldi, G., Bugarski-Kirola, D., Berardo, C. G., & Kapur, S. (2012). Negative symptoms have greater impact on functioning than positive symptoms in schizophrenia: Analysis of CATIE data. Schizophrenia Research, 137(1–3), 147–150. PubMedCrossRef Rabinowitz, J., Levine, S. Z., Garibaldi, G., Bugarski-Kirola, D., Berardo, C. G., & Kapur, S. (2012). Negative symptoms have greater impact on functioning than positive symptoms in schizophrenia: Analysis of CATIE data. Schizophrenia Research, 137(1–3), 147–150. PubMedCrossRef
Metagegevens
Titel
Health-related quality of life in patients with prominent negative symptoms: results from a multicenter randomized Phase II trial on bitopertin
Auteurs
Diana Rofail
Antoine Regnault
Stéphanie le Scouiller
Carmen Galani Berardo
Daniel Umbricht
Ray Fitzpatrick
Publicatiedatum
05-07-2015
Uitgeverij
Springer International Publishing
Gepubliceerd in
Quality of Life Research / Uitgave 1/2016
Print ISSN: 0962-9343
Elektronisch ISSN: 1573-2649
DOI
https://doi.org/10.1007/s11136-015-1057-9

Andere artikelen Uitgave 1/2016

Quality of Life Research 1/2016 Naar de uitgave